Lok Sabha approves bill to expand J&K pharmacists’ job opportunities

NEW DELHILok Sabha on Monday passed a bill allowing those qualified or registered under the Jammu & Kashmir Pharmacy Act to be registered as pharmacists under the Pharmacy Act, thus doing away with the ambiguity with regard to the two legislations.

Piloting the Pharmacy (Amendment) Bill, 2023, health minister Mansukh Mandaviya said changes will increase job opportunities for the youth of J&K.
The bill, which was passed by voice vote in the Lower House, seeks to do away with issues concerning the status of persons registered or qualified under the Jammu & Kashmir Pharmacy Act. Under the current dispensation, registration under the Pharmacy Act is mandatory for people practising pharmacy in the country.

He also said the situation in Jammu & Kashmir has changed significantly after abrogation of Article 370.

Related Posts

  • Pharma
  • July 11, 2025
  • 94 views
India’s Glenmark Pharma unit, AbbVie sign exclusive licensing pact

July:  India’s Glenmark Pharmaceuticals (GLEN.NS), opens new tab said on Thursday its innovation arm, Ichnos Glenmark Innovation (IGI), and AbbVie (ABBV.N), opens new tab have signed an exclusive licensing agreement…

  • Pharma
  • July 10, 2025
  • 155 views
Pills & Profits: Can India’s pharma sector handle Trump’s planned 200% tariff dose?

India stands tall as a pharmaceutical powerhouse, supplying 20% of the world’s generic medicines and nearly 62% of global vaccines. Yet, this success now faces a storm: US President Donald…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

India’s Glenmark Pharma unit, AbbVie sign exclusive licensing pact

India’s Glenmark Pharma unit, AbbVie sign exclusive licensing pact

Very Arty Surgery for Weight Loss by SSI Mantra, World’s First

Very Arty Surgery for Weight Loss by SSI Mantra, World’s First

Pills & Profits: Can India’s pharma sector handle Trump’s planned 200% tariff dose?

Pills & Profits: Can India’s pharma sector handle Trump’s planned 200% tariff dose?

Novartis wins approval for first malaria drug for newborns and babies

Novartis wins approval for first malaria drug for newborns and babies